S&P Futures
4,243.00 -43.50 (-1.01%) Dow Futures
33,702.00 -279.00 (-0.82%) Nasdaq Futures
13,370.50 -152.75 (-1.13%) Russell 2000 Futures
1,976.80 -24.90 (-1.24%) Crude Oil
88.42 -2.08 (-2.30%) Gold
1,764.50 -6.70 (-0.38%)
Krystal Biotech, Inc. (KRYS)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 73.93 |
| Open | 74.09 |
| Bid | 0.00 x 800 |
| Ask | 74.07 x 1000 |
| Day's Range | 72.05 - 74.88 |
| 52 Week Range | 38.86 - 102.99 |
| Volume | |
| Avg. Volume | 176,380 |
| Market Cap | 1.91B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.48 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 102.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for KRYS
Related Research
- Krystal Biotech, Inc.RGNX: Lowering target price to $19.00REGENXBIO INC has an Investment Rating of SELL; a target price of $19.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat2 months agoArgus Research
- GlobeNewswire
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the US Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for B-VEC for the treatment of patients with dystrophic ep
- GlobeNewswire
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments PITTSBURGH, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress updates for the second quarter ending June 30, 2022. “The B
- GlobeNewswire
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis (CF). KB40
